Hong Wan

Hong Wan

Company: Tallac Therapeutics

Job title: Chief Executive Officer

Seminars:

Speaker Q&A 12:55 pm

Read more

day: Day One

Targeted Immune Cell Activation by Systemic Delivery of Toll- Like Receptor 9 Agonist Antibody Conjugates Induce Potent Anti-Tumor Immunity 11:40 am

Novel therapies engaging both innate and adaptive immune responses may engender durable anti-tumor immunity Activation of toll-like receptor 9 (TLR9) by unmethylated CpG oligonucleotides promotes innate inflammatory responses and induction of adaptive immunity We developed a novel Toll-like Receptor Agonist Antibody Conjugate (TRAAC) platform to deliver a potent TLR9 agonist (T-CpG) for targeted immune activation…Read more

day: Day One

© Copyright 2018 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.